New targetable oncogenes in non-small-cell lung cancer

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Targeted therapies for non-small-cell lung cancer (NSCLC) have advanced significantly with the identification of driver oncogenes like EGFR and ALK.
• This success has spurred research into discovering additional actionable targets in NSCLC.
• Understanding these new targets is crucial for developing more effective personalized treatments.

Purpose of the Study:

• To review recently identified oncogenic driver alterations in NSCLC.
• To discuss the prevalence, preclinical evidence, and targeted inhibitor development for these new candidate oncogenes.
• To provide a comprehensive overview of emerging therapeutic targets in NSCLC.

Main Methods:

• Literature review of studies identifying and characterizing novel oncogenes in NSCLC.
• Analysis of prevalence data for specific gene alterations (BRAF, HER2, PIK3CA, FGFR1, DDR2, ROS1, RET).
• Examination of preclinical data and ongoing clinical trials for small molecule inhibitors targeting these alterations.

Main Results:

• Several new oncogenic alterations, including BRAF mutations, HER2 insertions, PIK3CA mutations, FGFR1 amplifications, DDR2 mutations, ROS1 rearrangements, and RET rearrangements, have been identified in NSCLC.
• Prevalence rates vary across these alterations.
• Promising preclinical data exists for small molecule inhibitors targeting these newly identified oncogenes, with several agents in clinical development.

Conclusions:

• The landscape of targetable oncogenes in NSCLC is expanding beyond EGFR and ALK.
• These newly identified alterations represent potential therapeutic targets for a subset of NSCLC patients.
• Further research and clinical trials are essential to validate the efficacy of targeted therapies for these emerging oncogenes in NSCLC.